Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $5.03, $0.05 worse than the analyst estimate of $5.08. Revenue for the quarter came in at $3.19 billion versus the consensus estimate of $3.18 billion.

GUIDANCE:

Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of $13.001 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.